Biopharma
By
Is Bayer’s Lawsuit Against Johnson & Johnson Escalating the Competitive Battle in Prostate Cancer Therapeutics?
Leverkusen, Germany — Bayer AG has filed a lawsuit in U.S. federal court against Johnson & Johnson, alleging…
Is Johnson & Johnson’s $1 Billion Pennsylvania Investment a Defining Bet on the Future of Cell Therapy?
New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1 billion to construct…
Innovent and Eli Lilly Expand Strategic Alliance to Advance Immunology and Oncology Innovation
Shanghai, China – February, 2026 – Innovent Biologics Inc today announced a new strategic collaboration with Eli Lilly…
Eli Lilly to Acquire Orna Therapeutics in Deal Valued at Up to $2.4 Billion to Advance In Vivo Cell Therapy Platform
Indianapolis, IN – February 9, 2026 – Eli Lilly and Company today announced it has entered into a…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology leadership via ImmunoGen Elahere acquisition ($10B…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1 global oncology leadership…
